SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14C - Other definitive information statements:
SEC Accession No. 0001047469-20-001128
Filing Date
2020-03-02
Accepted
2020-03-02 06:03:35
Documents
1
Period of Report
2020-03-02
Effectiveness Date
2020-03-02

Document Format Files

Seq Description Document Type Size
1 DEF 14C a2240830zdef14c.htm DEF 14C 301642
  Complete submission text file 0001047469-20-001128.txt   302984
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: DEF 14C | Act: 34 | File No.: 001-37418 | Film No.: 20674064
SIC: 2834 Pharmaceutical Preparations